Background: To assess the outcome of surgical resection in patients with primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT) with rising serum tumor markers (STM) following standard platinum-based chemotherapy.
introduction Extragonadal germ-cell tumors (GCT) most commonly originate in the retroperitoneum or the anterior mediastinum. Primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT) is an uncommon disease, accounting for 15% of adult anterior mediastinal tumors [1] and 5% of all GCT [2] . The serologic and histologic characteristics of PMNSGCT are similar to their primary testicular counterparts, but their biology and clinical outcomes are markedly different [3] [4] [5] . PMNSGCT are categorized as poor-risk disease regardless of any other variable [6] . Long-term survival of patients with PMNSGCT ranges between 30% and 60% [4, [7] [8] [9] [10] [11] [12] [13] . Currently, the standard therapeutic approach includes four courses of platinum-based chemotherapy followed by surgical resection of any radiographic evidence of residual disease [4, 8, [14] [15] [16] [17] . Relapsed patients have a poor response to salvage chemotherapy alone, with only 7% of patients attaining longterm disease-free survival [18] .
Rising serum tumor markers (STM) post-chemotherapy are usually considered a contraindication to surgery. There is very little data on the results of postchemotherapy resection in the face of rising STM for patients with PMNSGCT. In this article, we report on 35 patients who presented with PMNSGCT and had rising STM after standard first-line platinum-based chemotherapy. The purpose of this study was to report the results and outcome of surgical resection in this patient population. The investigational review board of our institution approved this study.
patients and methods
A retrospective chart review was carried out in 158 consecutive patients with PMNSGCT that were resected at Indiana University from 1982 to 2007. All patients received the standard chemotherapy regimen at the time (cisplatin-based chemotherapy) or were randomly assigned to an ongoing protocol.
Surgery to remove residual disease was carried out in all patients. The operation is typically delayed for 4-5 weeks after cisplatin completion, which allows functional status and bone marrow recovery. The goal is to achieve R0 resections (e.g. microscopic tumor-free margins). Multiple soft tissue margins for frozen sections are routinely sampled during mediastinal dissection at our institution for this patients' population. The details of our current surgical approach to the residual mass after chemotherapy has been described elsewhere [19] [20] [21] .
We defined rising STM as any increase in the preoperative STM value in comparison with the value taken after the final course of chemotherapy. We reviewed patient charts and, when necessary, local treating physicians were contacted to obtain follow-up survival information. The overall survival (OS) outcome was calculated from the time of surgical resection until death or last date known alive. The relapse-free survival outcome was calculated from the time of surgical resection until disease relapse.
results Thirty-five patients had rising STM after chemotherapy. Only one patient was a female and the rest were males. The median age of this group was 27 years (range 19-44 years). All patients had elevated STM [either alpha-fetoprotein (AFP) or human chorionic gonadotropin (hCG)] at the time of diagnosis. The median AFP was 5930 ng/ml (range normal to 147 000 ng/ml). The elevated hCG values were 21, 92, and 1500 mIU/ml. Our normal range for serum AFP is 0-25 ng/ml and for hCG is 0-3 mIU/ml.
histology
The histology of the resected residual disease included 24 patients (69%) with viable nonseminomatous germ-cell tumors (NSGCT) (embryonal cell carcinoma, yolk sac tumor, choriocarcinoma, or combination). Eight patients had teratoma and three had necrotic tissue only, despite the presence of rising STM prior resection. All these patients had microscopic tumor-free margins.
survival and outcomes
After surgical resection, 27 (77%) of the 35 patients normalized their STM. Twenty-one (60%) of 35 died, 5 (14%) were lost to follow-up, and 9 (26%) are alive. Of the 21 deaths, 18 patients have died from disease and three patients experienced postoperative mortality secondary to respiratory failure. All relapses were in distant metastatic sites (most commonly in the lungs). No local recurrences were reported in the resected surgical fields, implying the presence of microscopic extramediastinal disease at the time of surgery.
Of the nine patients alive, seven are continuously disease free, with a median follow-up of 64 months (25, 32, 63, 64, 82, 154 , and 220 months) after resection. Six of these seven patients had viable germ-cell cancer pathologically demonstrated in the resected mediastinal mass; two of them had also viable GCT in the resected pulmonary parenchyma. Two patients (6%) are alive with active disease at the time of this report.
The median OS for the patients who had a follow-up survival information (n = 30) was 11.5 months (range 2-220 months), and the median overall relapse-free survival was 3 months (range 1-220 months).
outcome by extent of disease at presentation Twenty-four patients had disease confined to the mediastinum at time of initiation chemotherapy. Ten patients had lung involvement, and three patients had extrathoracic involvement of the liver or brain ( Table 1) . The three patients with extrathoracic disease at presentation have all died. Two of the eight patients who had lung or pleural involvement without extrathoracic metastasis at presentation are continuously disease free with a follow-up of 32 and 82 months.
outcome by histology of resected disease At resection, 24 patients (69%) were found to have histologic evidence of viable NSGCT (embryonal cell carcinoma, yolk sac tumor, choriocarcinoma, or combination), 8 patients (23%) had teratoma only, and 3 patients (9%) had necrosis only. Of 24 patients with viable NSGCT histology, 5 are continuously disease free with median follow-up of 63 months (range 25-82 months), 13 patients died from disease, 1 patient died postoperatively, and 5 were lost to follow-up. Of 11 patients with nonviable GCT histology (i.e. teratoma or necrosis), only 2 are continuously disease free with follow-up of 154 and 220 months ( Table 2 ).
The median OS for patients with viable tumor and nonviable tumor who had a follow-up survival information are 13.5 and 12 months, respectively. Follow-up of STM levels postoperatively showed normalization of all patients with necrosis, 20 of 24 patients with viable GCT and only 4 of 8 (50%) patients with teratoma.
Those patients who had resection of viable germ-cell cancer and normalized their postoperative tumor markers were usually observed rather than offered subsequent chemotherapy. This is because the majority of these patients were felt to be cisplatin and etoposide refractory because of the rising tumor markers in close proximity to their last course of induction chemotherapy. Only one of the seven patients continuously disease free after surgery received postoperative chemotherapy. This patient failed to normalize his STM postoperatively and received salvage chemotherapy. He did not experience a rise in STM before instituting salvage chemotherapy. discussion PMNSGCT represents a rare disease [1, 2] , and therefore, data concerning outcome analyses with or without surgical resection have been limited by the paucity of cases. The cure rate with GCT, germ-cell tumors; STM, serum tumor markers.
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this disease is inferior to primary testicular NSGCT and reflects a distinctly different biologic behavior despite similar histology [4] . PMNSGCT is classified as a poor-risk disease regardless of any other prognostic variables [6] . Surgical treatment in the presence of rising STM after chemotherapy has been controversial. Second-line salvage chemotherapy has been well established for testicular NSGCT refractory to first-line chemotherapy [22] . However, secondline salvage chemotherapy has not been effective for PMNSGCT. Hartmann et al. [23] found that second-line chemotherapy for 79 patients with PMNSGCT provided only 11% long-term disease-free survival. Moreover, a mediastinal NSGCT origin was independently predictive of a negative response to second-line chemotherapy in their study compared with retroperitoneal primary.
Surgical resection of PMNSGCT following front-line platinum-based chemotherapy is typically undertaken at Indiana University regardless of the STM status [24] . This is because of poor results with salvage chemotherapy [12, 18, 23, [25] [26] [27] [28] and the efficacy with salvage surgery [17, 24] . However, there is little or no data on resection in patients with PMNSGCT after chemotherapy with rising STM. The STM status after completion of platinum-based chemotherapy does not always reflect the presence of residual cancer [29] .
Outcome was evaluated by histology. There was no clinically meaningful difference in median OS between the patients who had viable GCT versus those who had nonviable GCT. Since only 2 of the11 patients with nonviable GCT are continuously disease free, this indicates either a pathological miss or presence of viable cancer outside the resected field. A pathologic sampling error could lead to failure to detect viable tissue in the resected bulky mass. The presence of distant metastasis is possible also, especially since the STM for 4 of 8 patients with teratoma failed to normalize postoperatively.
All the three postoperative deaths in our cohort had received bleomycin-containing chemotherapy regimens, which have traditionally been the standard of care for patients with poorrisk NSGCT, including PMNSGCT. Although no significant decrease in the diffusion capacity was observed preoperatively, subclinical pulmonary toxicity is likely, which is exacerbated by large thoracic surgical resection [30] .
Our current recommendation is to utilize VIP (etoposide, ifosfamide, and cisplatin) rather than BEP (bleomycin, etoposide, and cisplatin) for initial chemotherapy for patients with PMNSGCT. These two regimens are therapeutically equivalent [31] . In patients with advanced germ-cell tumors, ifosfamide is associated with increased nausea, vomiting, and myelosuppression, but devoid of pulmonary toxicity. Adapting this posture past decade, no patients experienced a postoperative death due to pulmonary toxicity.
We currently believe that an extensive and experienced surgical approach after cisplatin-based chemotherapy can result in long-term survival even in patients with persistent viable cancer, rising STM, or both and is warranted in these otherwise young and healthy patients. The use of non-bleomycincontaining regimens, such as VIP, appears to reduce the operative risk. However, surgery is technically demanding because the residual mass is typically infiltrating into surrounding mediastinal structures after chemotherapy. In our opinion, the skill and experience of the oncology center and especially the expertise of the thoracic surgical oncologist are of pivotal importance in achieving successful outcome. references
